Biotechnology, Pharmaceutical and Life Science Reports and Courses

Main Pages

Best Selling Products

BioNewsCast Press Release Distribution Service

Vaccine Technology 2009 Conference

Veterinary Diagnostics Markets

Practical Guide to Finding Partners in Pharma & Biotech, 2nd edition

Royalty Financing Agreements in Pharma, Biotech and Diagnostics

New Products

Attention Deficit Hyperactivity Disorder: Diagnosis and Treatment

Bioinformatics Market Potential

Biotechnology in the European Union; Trends, Investing & Country Profiles

China Pharmaceutical Industry: Analysis and Market Trends

European Generic Drug Market Potential

Global Biotechnology Markets Trends

Strategic Alliances in World Pharma and Biotech Markets

Understanding China's Chemical Industry

Understanding Genomics and Global Health Impacts

Understanding Pharmacogenomics

BioPortfolio | BioPolaris | Diabetes: Potential In-Licensing & Out-Licensing R and D Asian Companies

Diabetes: Potential In-Licensing & Out-Licensing R and D Asian Companies

Due to increased incidence and prevalence of diabetes in Asian countries, a significant number of Asian pharmaceutical companies are involved in development of new therapeutic compounds for the treatment of diabetes. On the other hand, the economic growth of Asia, particularly China and India, will enable better health care and treatment of their patients, meaning that biopharmaceutical and pharmaceutical markets are coming to a new age.

According to the the new data from the World Health Organization (WHO), there will be approximately 366 million patients diagnosed with diabetes in 2030, of which over 180 million in Asia. Including the number of people which have diabetes still not diagnosed, the quoted numbers may be almost doubled, with clear implication that market for anti-diabetic therapeutic products is increasing rapidly and will be enormous, particularly in Asia (Table 1).

This is one of the reasons that all major pharmaceutical companies are opening their business units and new manufacturing plants in Asia. At least nine European and USA pharmaceutical companies are involved in co-development of new anti-diabetes products with Asian companies, including F. Hoffmann-La Roche AG (Switzerland), a business unit of Roche Holding AG (Switzerland), GlaxoSmithKline plc (UK) and Johnson & Johnson (USA).

The new report from BioPolaris: Diabetes: Potential In-Licensing & Out-Licensing R & D Asian Companies features companies involved in development of new anti-diabetes products, features total of 36 companies, of which 19 are from Japan, 6 from South Korea, 5 from China, 5 from India and one from Taiwan.

Majority of them are looking to out-license or in-license R & D products for the treatment of diabetes.

Asian pharmaceutical companies are developing total of 55 new R & D compounds for the treatment of diabetes and diabetes complications.

Each company data include its name, address, phone and fax number, web site, public or private information and pipeline of R & D products for the treatment of diabetes.

Published: August 2009 Pages: 38
Table 1
Price: $1,150.00 / €768.66

BioPortfolio uses RBS Worldpay Secure Server for credit card transactions